Drug Approval | August 19, 2022
Lupin receives approval from U.S. FDA for Rufinamide Tablets USP
The product will be manufactured at Lupin's facility in Goa, India.
The product will be manufactured at Lupin's facility in Goa, India.
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.
Meclizine Hydrochloride Tablets had estimated annual sales of USD 29 million in the U.S.
Quetiapine Extended-Release Tablets are indicated for the treatment of Schizophrenia, Bipolar disorder and adjunctive treatment of Major Depressive Disorder (MDD)
The product will be manufactured at Lupin’s facility in Goa, India.
Apollo Hospital Group completed the acquisition of a hospital asset in Gurugram for a consideration of around Rs 450 crore.
Lupin is the 6th largest company in the Indian Pharmaceutical Market
The company is focused on therapies such as skinceuticals, gastroenterology, neuropsychiatry, cardiac diabetes care etc.
Supports development and commercialization of complex oral drugs using sensitive molecules, including biologicals
Subscribe To Our Newsletter & Stay Updated
